Adani Enterp. 2429.15↓-10.40(-0.43%)
Adani Ports 736.40↓-7.35(-0.99%)
Apollo Hospitals 4926.65↓-99.80(-1.99%)
Asian Paints 3212.25↓-12.55(-0.39%)
Axis Bank 962.10↓-14.65(-1.50%)
B P C L 361.10↓-7.00(-1.90%)
Bajaj Auto 4800.65↑19.90(0.42%)
Bajaj Finance 7010.10↓-69.85(-0.99%)
Bajaj Finserv 1467.40↓-13.50(-0.91%)
Bharti Airtel 836.00↓-8.25(-0.98%)
Britannia Inds. 4875.05↓-18.10(-0.37%)
Cipla 965.40↑4.95(0.52%)
Coal India 228.10↓-2.60(-1.13%)
Divi's Lab. 3499.70↓-42.40(-1.20%)
Dr Reddy's Labs 4649.40↓-24.35(-0.52%)
Eicher Motors 3657.40↓-70.00(-1.88%)
Grasim Inds 1711.95↓-57.10(-3.23%)
H D F C 2653.80↑5.25(0.20%)
HCL Technologies 1126.75↓-2.30(-0.20%)
HDFC Bank 1608.70↑1.00(0.06%)
HDFC Life Insur. 593.90↓-0.55(-0.09%)
Hero Motocorp 2964.80↑6.80(0.23%)
Hind. Unilever 2679.90↓-36.30(-1.34%)
Hindalco Inds. 418.25↓-4.35(-1.03%)
ICICI Bank 937.90↓-2.30(-0.24%)
IndusInd Bank 1303.85↓-7.35(-0.56%)
Infosys 1282.80↓-6.15(-0.48%)
ITC 442.90↓-1.05(-0.24%)
JSW Steel 748.80↑19.05(2.61%)
Kotak Mah. Bank 1886.50↓-52.90(-2.73%)
Larsen & Toubro 2340.30↑24.80(1.07%)
M & M 1381.05↓-25.35(-1.80%)
Maruti Suzuki 9658.60↓-48.90(-0.50%)
Nestle India 22148.90↓-218.85(-0.98%)
NTPC 182.05↑4.70(2.65%)
O N G C 156.10↑2.25(1.46%)
Power Grid Corpn 241.65↑2.45(1.02%)
Reliance Industr 2499.65↑1.50(0.06%)
SBI Life Insuran 1238.90↓-6.90(-0.55%)
St Bk of India 588.50↓-0.70(-0.12%)
Sun Pharma.Inds. 987.00↓-27.60(-2.72%)
Tata Consumer 807.10↓-16.00(-1.94%)
Tata Motors 559.70↓-8.25(-1.45%)
Tata Steel 111.15↓-0.35(-0.31%)
TCS 3236.45↓-38.45(-1.17%)
Tech Mahindra 1071.30↓-24.40(-2.23%)
Titan Company 2877.00↓-29.95(-1.03%)
UltraTech Cem. 8100.15↓-57.45(-0.70%)
UPL 690.05↓-3.90(-0.56%)
Wipro 399.55↓-3.25(-0.81%)

In a nation of inequalities, India's vaccine strategy is bad economics

Free, universal access to inoculation could prepare India better for a third Covid-19 resurgence.

Coronavirus, vaccine, covid, drugs, vaccination, innoculation

Premium

5 min read Last Updated : Apr 27 2021 | 9:17 PM IST

After a tightly centralized vaccination drive that has delivered the required two shots to less than 2% of the population, India is opening up its inoculation strategy in the middle of a raging pandemic. Can the new approach flatten the curve?

Expanding the campaign to all adults below 45 starting next month is a late but welcome move. India’s daily infection rate of almost 350,000 is the worst any country has experienced. Even then, shifting a big part of the financial burden to 28 state governments and letting private hospitals buy shots at 600 to 1200 rupees ($8 to $16) apiece--and sell them to patients at even higher prices--are both wrong.

In a nation riddled with inequalities and swelling with 75 million newly impoverished after last year’s coronavirus lockdown, putting a price on any part of limited vaccine supplies could lead to unjust, lopsided distribution. Free, universal access, with New Delhi negotiating prices with at